Navigation Links
Pharmasset Adds Two Cohorts to R7128 Hepatitis C Study
Date:4/24/2008

get="_new">http://www.clinicaltrials.gov or e-mail clinicaltrials@pharmasset.com for more information.

Conference Call

Pharmasset will host a conference call at 1:00 PM ET (US) and 7:00 PM CEST (Milan) on Friday, April 25, 2008 to discuss the addition of two R7128 cohorts, as well as the results of the 4-week combination study of R7128 presented at EASL.

Dial-in Information:

US/Canada Toll-Free callers: +1 (877) 545-1490

US/Canada Toll or International Toll callers: +1 (719) 325-4884

Live audio of the conference call will be simultaneously broadcast over the internet via a webcast. To access the live webcast, log on to the "Events & Presentations" section of the Investor Center on Pharmasset's corporate website at http://investor.pharmasset.com/events.cfm.

Please connect to the company's website at least ten minutes prior to the start of the presentation to ensure adequate time for a reliable connection and any software download that may be necessary to listen to the webcast. The archived replay of the webcast will be available on the Pharmasset website for two weeks following the conference call.

About R7128

R7128 is being developed for the treatment of chronic HCV infection. R7128 is a prodrug of PSI-6130, a cytidine nucleoside analog inhibitor of HCV RNA polymerase. A prodrug is a chemically modified form of a molecule designed to enhance the absorption, distribution and metabolic properties of that molecule. Results from an oral single ascending dose study of PSI-6130 in 24 healthy male volunteers showed that PSI-6130 was generally well tolerated with no serious adverse events in doses up to 3000 mg.

R7128 demonstrated potent, dose-dependent antiviral activity across four prior treatment-failure patient cohorts (n=40) receiving 750 mg or 1500 mg administered either once-daily or twice-daily for 14 days as monotherapy
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Pharmasset to Present at the Canaccord Adams Hepatitis C Conference on Wednesday, April 9th
2. Pharmasset Receives $10 Million of Working Capital
3. Pharmasset Appoints Herbert J. Conrad as a Director
4. Pharmasset to Present at Cowen & Companys Health Care Conference on Tuesday, March 18th
5. Pharmasset to Present at Susquehannas Second Annual SIGnificant Investment Options in Healthcare Conference on Wednesday, March 5th
6. Pharmasset to Present at the BIO CEO & Investor Conference 2008 on Monday, February 11th
7. Pharmasset Reports Fiscal Year End 2007 Financial Results
8. Pharmasset Appoints Michael Rogers as Chief Development Officer
9. Pharmasset to Present at Three Investor Conferences in November 2007
10. Pharmasset Accesses up to $30 Million of Working Capital
11. Pharmasset to Present at the UBS Global Life Sciences Conference on Monday, September 24th
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... July 24, 2014 1000 balances – ... input on customers’ weighing needs and expertly narrows down ... of balances, scales or even terminals. , First, ... smallest weight (or select readability instead) and define the ... additional selection criteria narrows down the list to models ...
(Date:7/24/2014)... 2014   Cypher Genomics, Inc., the ... Adam Simpson as president and chief ... comprehensive annotation and interpretation of individual human genomes ... "Cypher,s technology has the potential to play a ... accuracy, optimizing therapeutic approaches and reducing adverse drug ...
(Date:7/23/2014)... Arab Emirates (UAE) (PRWEB) July 23, 2014 ... Century recently announced that its biobanking project, ... , Ph.D. to its growing Advisory Board. Scott ... very pleased to have Dr. Vaught onboard with Provia’s ... depth and expertise that Provia’s management team brings to ...
(Date:7/23/2014)... Dresden-Rossendorf (HZDR), the Vienna University of Technology and ... embedding nearly perfect semiconductor crystals into a silicon ... nanowires, very fast and multi-functional processing units can ... future. The research results will be published in ... are considered the cornerstone of future chip technology, ...
Breaking Biology Technology:Cypher Genomics Announces the Appointment of Adam Simpson as President and COO to Advance Transformative Genome Interpretation Technology 2Cypher Genomics Announces the Appointment of Adam Simpson as President and COO to Advance Transformative Genome Interpretation Technology 3Provia Laboratories Adds Dr. Jim Vaught, Ph.D., Former Chief of BBRB, to Advisory Board 2Provia Laboratories Adds Dr. Jim Vaught, Ph.D., Former Chief of BBRB, to Advisory Board 3Provia Laboratories Adds Dr. Jim Vaught, Ph.D., Former Chief of BBRB, to Advisory Board 4A crystal wedding in the nanocosmos 2
... NEOG ) announced today that despite obstacles ... revenues increased 11% to $27,840,000, a record third quarter ... $25,180,000. Year-to-date, nine-month revenues rose 17% in the current ... Year-to-date net income for the first nine ...
... Strengthen Expertise in Immunotherapy of CancerBETHESDA, Md., March ... ), a biopharmaceutical company developing novel, proprietary antibodies ... diseases, today announced the the appointment of Sir ... antibody advisory panel. Other members of the company,s ...
... Company estimates sales of pixantrone, if approved, could potentially ... Philips, President of Cell Therapeutics, Inc. (CTI) (NASDAQ and ... the 8th Annual WBBA Invest Northwest Conference on Wednesday, ... CTI,s pixantrone program for treatment of aggressive relapsed non-Hodgkin,s ...
Cached Biology Technology:Neogen Reports Record Third Quarter 2Neogen Reports Record Third Quarter 3Neogen Reports Record Third Quarter 4Neogen Reports Record Third Quarter 5Neogen Reports Record Third Quarter 6Micromet Adds Sir Walter Bodmer and Bernard Fox to Its Advisory Panel for BiTE Antibody Therapeutics 2Micromet Adds Sir Walter Bodmer and Bernard Fox to Its Advisory Panel for BiTE Antibody Therapeutics 3Micromet Adds Sir Walter Bodmer and Bernard Fox to Its Advisory Panel for BiTE Antibody Therapeutics 4Micromet Adds Sir Walter Bodmer and Bernard Fox to Its Advisory Panel for BiTE Antibody Therapeutics 5Cell Therapeutics Presents Corporate Highlights at Invest Northwest Conference 2Cell Therapeutics Presents Corporate Highlights at Invest Northwest Conference 3
(Date:7/24/2014)... the product of 3.5 billion years of evolutionary trial ... life. But it may be reaching a tipping point. ... analysis of data published in Science , an ... decline of animals is contributing to what appears to ... biological extinction event. , Since 1500, more than 320 ...
(Date:7/24/2014)... A multi-institutional team of researchers has developed a new ... safe, noninvasive method for assessing the function and properties ... to better diagnosis and treatment of gut diseases. ... irritable bowel syndrome and inflammatory bowel disease all occur ... effects in patients with diseases such as diabetes and ...
(Date:7/24/2014)... affect the connections between nerve cells and influence the ... of the brain that plays a significant role in ... of the study have been published in the journal ... active communication between nerve cells, known as neurons. For ... network where they constantly relay signals to one another. ...
Breaking Biology News(10 mins):Stanford biologist warns of early stages of Earth's 6th mass extinction event 2Stanford biologist warns of early stages of Earth's 6th mass extinction event 3New imaging agent provides better picture of the gut 2A protein couple controls flow of information into the brain's memory center 2A protein couple controls flow of information into the brain's memory center 3A protein couple controls flow of information into the brain's memory center 4
... of chemists from the University of Valencia (UV) has ... amphora found among remains at Lixus, in Morocco, was ... inside the 2,000-year-old vessel, which could be fragments of ... of archaeologists from the UV discovered a sealed amphora ...
... Although they are present almost everywhere, on land ... the superphylum Planctomycetes-Verrucomicrobia-Chlamydiae, or PVC, have remained in ... about a decade ago. Scientists at the European ... discovered that these poorly-studied bacteria possess proteins thought ...
... The Genetics Society of America is pleased to announce ... for Professional Development in Genetics. These travel ... and international meetings or enroll in laboratory courses. ... DeLill Nasser (1929-2000), who was instrumental in promoting genetics ...
Cached Biology News:Chemical analyses uncover secrets of an ancient amphora 2Membrane-coat proteins: Bacteria have them too 2
... Synaptogyrin 2 ( Abpromise ... Antigen: Synthetic ... sequence amino acids 42-57 of ... Entrez Gene ID: ...
Rabbit polyclonal to SMURF 2 ( Abpromise for all tested applications). Antigen: A KLH conjugated synthetic peptide (10-30 aa in length) at the N-term of first 50 aa of human SMURF 2. Entrez G...
Rabbit polyclonal antibody to NCOA2 [Agarose Immobilized]...
Rabbit anti Mouse ZIC2 Preservative: NaN3...
Biology Products: